Results of high dosage progesterone therapy in carcinoma corporis uteri
Seewald, H.J.; Böhm, W.; Przesang, R.
Zentralblatt für Gynakologie 99(7): 392-395
1977
ISSN/ISBN: 0044-4197 PMID: 868363 Document Number: 115144
High dosage gestagen therapy is indicated for progressive endometrial carcinomas when there are recurring or metastasizing tumors or the presence of extensive tumors suggesting incomplete surgical removal. Both norethisterone acetate in dosages of 20-30 mg die and hydroxyprogesterone capronate in dosages of 1-5 gm weekly are well tolerated. Interruption of medication is to be avoided, since recurrences have been noted even after discontinuation of successful long-term therapy. In 60-70% of the patients, general and localized improvements were observed. A hemostatic effect usually occurred during the 1st week of treatment. Avoidance of local recurrence and an average survival period of 34 months after detection of lung metastasis as well as cases of complete remission speak highly for the therapy. Low dosage, short-term progesterone treatment for all cases of endometrial carcinoma is not recommended at the present time.